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non-inferior to enoxaparin/VKA for recurrent VTE (HR: 1.12, 95%CI 0.75-1.68) and 
demonstrated a significant reduction in major bleeding (HR: 0.49, 95%CI 0.31-0.79, 
P= 0.003). STUDY QUESTION: What is the incremental cost/QALY gained, from a 
Canadian provincial government perspective, for rivaroxaban compared to LMWH/
VKA for treatment of PE, over a 5 year horizon? Methods: A Markov model was 
developed. Patients entered the model with an index PE and required 3, 6 or 12 
months of treatment. Patients were exposed to treatment-specific risks of recurrent 
VTE and bleeding events, and associated mortality and long-term complications. 
Clinical inputs were from EINSTEIN-PE and published literature. Economic inputs 
were from publically available Canadian sources. Consistent with EINSTEIN-PE, 
a reduction in hospital length of stay was included for admitted patients treated 
with rivaroxaban. Utility inputs were from published literature. Extensive sensi-
tivity analyses were conducted. Results: Rivaroxaban dominated LMWH/VKA at 
all treatment durations examined. In patients appropriate for 3, 6 and 12 months 
treatment, rivaroxaban demonstrated per patient cost savings of $629, $561 and $341 
($CAN), and QALY gains of 0.002, 0.004 and 0.005, respectively. Findings were robust 
to sensitivity analysis. ConClusions: Rivaroxaban is a cost-effective treatment for 
PE, dominating LMWH/VKA for patients requiring up to 12 months treatment. The 
positive clinical and economic profiles of rivaroxaban together make it a valuable 
treatment option for Canadian PE patients and payers.
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objeCtives: To examine the economic burden and health care utilizations of 
post-traumatic stress disorder (PTSD) after unstable angina (UA) in the U.S. vet-
eran population. Methods: A retrospective database analysis was conducted using 
the Veterans Health Administration Medical SAS datasets (01OCT2007-30SEP2012). 
Adult patients with a PTSD diagnosis (International Classification of Disease, 9th 
Revision, Clinical Modification [ICD-9-CM] code: 309.81) were identified. The first 
PTSD diagnosis date was designated as the index date. UA diagnosis (ICD-9-CM 
codes: 411.1, 411.81, 411.89) was required 1 month before the first PTSD diagnosis 
during the baseline period. A comparator group was created by identifying patients 
without PTSD using 1:1 propensity score matching, with covariates including age, 
region, gender, index year and baseline Charlson comorbidity index score. A ran-
domly-chosen index date for the comparator group reduced selection bias. One-
year continuous enrollment was required before and after the index date for both 
groups. Health care costs and utilizations were compared between the disease and 
comparator groups in the matched sample. Results: After 1:1 matching, a total 
of 341 patients were matched from each group with well-balanced baseline char-
acteristics. Patients diagnosed with UA-induced PTSD had significantly more inpa-
tient admissions (21.41% vs. 2.64%, p< 0.0001) and emergency room (ER) (32.84% vs. 
10.56%, p< 0.0001), physician office (99.12% vs. 78.30%, p< 0.0001), outpatient (99.12% 
vs. 79.77%, p< 0.0001) and pharmacy visits (97.07% vs. 82.99%, p< 0.0001). Higher 
health care utilizations translated to higher costs for UA-induced PTSD patients, 
including inpatient ($4,406 vs. $731, p< 0.0001), ER ($349 vs. $82, p< 0.0001), physician 
office ($5,934 vs. $2,304, p< 0.0001), outpatient ($6,679 vs. $2,492. P< 0.0001), pharmacy 
($1,146 vs. $570, p< 0.0001) and total costs ($12,231 vs. $3,793, p< 0.0001), relative to 
those in the comparison group. ConClusions: The study results suggest that the 
economic burden and health care utilizations were significantly higher for patients 
diagnosed with PTSD after UA diagnosis versus those without.
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objeCtives: Both Thiazide-diuretics and angiotensin-converting enzyme inhibi-
tors (ACEI) have similar efficacy in treating hypertension in elderly though ACEI is 
costlier. Using diuretic is associated with increased risk of developing new-onset 
diabetes compared to ACEI. To date evidence is lacking on the cost-effectiveness 
(CE) of ACEI compared to diuretic-based treatment considering diabetes develop-
ment as part of treatment. This study aims to determine the CE of ACEI compared 
to thiazide-diuretic based treatment of hypertension in the elderly in an Australian 
context. Methods: A cost-utility analysis was undertaken using real data from the 
Second Australian National Blood Pressure Study, a randomized clinical trial com-
paring diuretic-based versus ACEI-based treatment in an elderly (age ≤ 65yr) hyper-
tensive population over a median 4.1-year period. Three models were used: 1) ‘model 
A’ includes all study subjects without considering diabetes at any stage (n= 6072); 
2) ‘model B’ includes diabetes-free subjects at the start (n= 5616); and 3) ‘model C’ 
includes subjects with diabetes at the start (n= 422) of the trial. One-way and proba-
bilistic sensitivity analyses were performed to assess the uncertainty. Results: CE 
analyses showed that in model A, the quality-adjusted life-year (QALY) gained was 
0.004 per person for ACEI-based treatment compared to diuretic-based treatment 
and the incremental cost-effectiveness ratio (ICER) per QALY gained was AUD 62,472. 
For model B, there was 0.009 QALY’s gained per-person and the ICER per QALY gained 
being AUD 29,535. Model C was a dominant strategy (cost-saving). On sensitivity 
analysis, the ICER per QALY gained for model B and C were always below AUD50,000; 
whereas for model A the probability was 25%. ConClusions: Initial treatment with 
diuretic-based treatment of hypertension in the elderly is less expensive, but con-
sidering the potential enhanced likelihood of development of diabetes in addition 
to costs of cardiovascular disease, ACEI-based treatment might be a cost-effective 
and safer alternative in this patient group.
PCV94
WhAT is The VAlue of ConduCTing A TriAl of r-TPA for The TreATmenT 
of mild sTroke PATienTs?
Guzauskas G.F.1, Lalla D.2, Yu E.2, Tayama D.2, Veenstra D.L.1
1University of Washington, Seattle, WA, USA, 2Genentech, South San Francisco, CA, USA
objeCtives: To demonstrate the use of value of information analyses to esti-
mate the value of the prospective Potential of r-tPA for Ischemic Strokes with Mild 
Symptoms (PRISMS) trial studying recombinant tissue plasminogen activase (r-tPA) 
for the treatment of mild stroke patients. Methods: We programmed a value 
of information decision model comparing the outcomes of mild stroke patients 
who were treated vs. not treated with r-tPA. We modeled specific stroke severity 
health states based on modified Rankin scores using Markov modeling techniques. 
Preliminary estimates of r-tPA effectiveness in mild patients were derived from a 
subset of International Stroke Trial-3 patients. Utility and cost inputs were derived 
from other published sources. Model simulations assessed the expected value of 
the prospective trial and the expected value of reducing uncertainty in key trial 
estimates. Results: At a societal willingness-to-pay per quality-adjusted life year 
of $100,000, the PRISMS trial’s expected value of sample information was approxi-
mately $1.1 billion. Uncertainty reduction in the absolute difference in nondisabled 
patients (mRS 0-1) between strategies had the greatest expected value at $963 mil-
lion, followed by uncertainty reduction in the mRS distribution of r-tPA patients at 
$466 million. Reducing uncertainty in costs, long-term life expectancy, and utility 
measures did not offer any additional societal value. ConClusions: Our analysis 
suggests a prospective trial of r-tPA for mild stroke patients seems justified based 
on the potential value of research. The trial’s expected benefits could be compared 
to those of other competing research proposals when prioritizing future research 
funding.
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objeCtives: Little is known on how pulmonary arterial hypertension (PAH) may 
impact worker productivity. The objective of this study was to estimate indirect 
costs of PAH in an employed population. Methods: Data came from Truven’s 
MarketScan Health and Productivity Management database. PAH workers were 
identified based on having > 2 medical claims for primary pulmonary hyperten-
sion (ICD-9 code:416.0), and either one claim for right heart catheterization or one 
claim of echocardiogram. The first medical claim during this period served as in 
the index date with 6 months prior to this event as baseline and 12 months post as 
follow-up period. Three non-PAH employees were matched to each PAH worker on 
age, gender, census region, and plan type. Annual productivity loss was calculated 
as a sum of absenteeism and short term disability (STD) in the follow-up year and 
derived by multiplying the reported days off work times the industry-specific aver-
age daily wage rate obtained from the 2012 US Department of Labor. Results: 72 
and 187 PAH workers met the absentee and STD eligibility benefits. The average age 
was approximately 50 years; over 52% were females, majority from the south region 
and enrolled in a preferred provider organization type health plan. Approximately 
90% of PAH patients held a full-time position, majority were either salaried or a 
non-Union hourly wage earner and employed in a manufacturing or transportation 
type of industry. The average daily wage rate was estimated at $191.20. In one-year, 
PAH workers on average had significantly higher absentee (33 vs. 23.6) and STD days 
(29.6 vs. 7.3) compared to the control group, respectively. Based on the daily wage 
rate the average annual productivity loss was $8,686 vs. $4,822 for PAH and non-PAH 
employees. ConClusions: Productivity loss among PAH workers was found to be 
44% higher than non-PAH employees.
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objeCtives: Heart failure (HF) patients are frequently hospitalized, resulting in 
reduced quality of life and increased health expenditures. This study estimates 
recent rates of hospitalizations among systolic HF patients in the US. Methods: 
This retrospective study used a large, nationally representative commercial data-
base. Adult patients aged 18-64 years with ≥ 1 inpatient or ≥ 2 outpatient diagnoses 
of systolic HF (ICD-9-CM 428.2x, 428.4x) in 2008-2013 with ≥ 12-months of claims 
data prior to and ≥ 1-month claims data after the first systolic HF diagnosis were 
included. Number of hospitalizations per patient-year of all-cause hospitalizations 
and hospitalizations with HF as a discharge diagnosis during the entire follow up 
were summarized. Hospitalization rates after patients had 1, 2, and 3 all-cause 
hospitalizations were also reported. Results: A total of 25,830 patients (mean 
age= 54 (SD 8.6); 63% male; 34% hypertension; 26% diabetes; 21% dyslipidemia; 20% 
arrhythmias) met the study criteria, with a mean follow up of 19 (SD 14.7) months. 
67.8% of patients were hospitalized during the follow up, 29.3% had 2+, 16.1% had 
3+ hospitalizations. During the entire study period following the systolic HF diag-
nosis, the mean numbers of hospitalizations per patient-year were 1.63 (SD= 2.62) 
for all-cause and 1.22 (SD= 2.16) for HF hospitalizations. After the first all-cause 
hospitalization, the mean number of subsequent hospitalizations per patient-year 
was 1.02 (SD= 2.17) for all-cause and 0.50 (SD= 1.45) for HF hospitalizations. The 
annualized rates for subsequent hospitalizations were higher after the 2nd and 3rd 
all-cause hospitalizations. ConClusions: From the time of diagnosis with systolic 
HF, hospitalizations are common and some patients experience multiple hospi-
talizations per year. The risk of subsequent hospitalizations increased in subjects 
